Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis;Néphropathie lupique stade IV chez une patiente traitée par étanercept pour un rhumatisme psoriasique

Nephrologie et Therapeutique

Volumn 6, Issue 6, 2010, Pages 537-540

  Sacquépée, Mathieu ^a,b   Rouleau, Vincent ^b   Cantin, Jean Franois ^b   Quirin, Nicolas ^b   Doussy, Yves ^a   Valéry, Jean Claude ^a   Picu, Cristina ^b   Tivollier, Jean Michel ^b  

^a Association Pour le Traitement de l'Insuffisance Rénale en Nouvelle Calédonie   (Canada)

^b Centre Hospitalier Territorial   (Canada)

Author keywords

Etanercept; Glomerulonephritis; Lupus; Tumor necrosis factor

Indexed keywords

AUTOANTIBODY; ETANERCEPT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CELLULITIS; DEBRIDEMENT; DRUG WITHDRAWAL; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PSEUDOMONAS AERUGINOSA; PSORIATIC ARTHRITIS; SEPTIC SHOCK;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CELLULITIS; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS NEPHRITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; SHOCK, SEPTIC;

EID: 78149413355     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2010.05.003     Document Type: Article

References (19)

1. M. De Bandt, J. Sibilia, X. Le Loët, S. Prouzeau, B. Fautrel, and C. Marcelli Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey Arthritis Res Ther 7 3 2005 R545 R551
2. H. Haake, J. Köneke, K. Amann, J. vom Dahl, and U. Janssen Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-α therapy for psoriatic arthritis Med Klin (Munich) 102 10 2007 852 857
3. A. Mor, C. Bingham 3rd, L. Barisoni, E. Lydon, and H.M. Belmont Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept J Rheumatol 32 4 2005 740 743
4. M.B. Stokes, K. Foster, G.S. Markowitz, F. Ebrahimi, W. Hines, and D. Kaufman Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis Nephrol Dial Transplant 20 7 2005 1400 1406
5. M. Ramos-Casals, P. Brito-Zerón, S. Muñoz, N. Soria, D. Galiana, and L. Bertolaccini Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases Medicine (Baltimore) 86 4 2007 242 251
6. A. Fournier, A. Nony, and K. Rifard Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis Nephrol Ther 5 7 2009 652 657
7. P.J. Charles, R.J. Smeenk, J. De Jong, M. Feldmann, and R.N. Maini Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials Arthritis Rheum 43 11 2000 2383 2390
8. T. Jonsdottir, J. Forslid, A. van Vollenhoven, A. Harju, S. Brannemark, and L. Klareskog Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies Ann Rheum Dis 63 9 2004 1075 1078
9. M.C. Bickerstaff, M. Botto, W.L. Hutchinson, J. Herbert, G.A. Tennent, and A. Bybee Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity Nat Med 5 6 1999 694 697
10. A.I. Russell, D.S. Cunninghame Graham, C. Shepherd, C.A. Roberton, J. Whittaker, and J. Meeks Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus Hum Mol Genet 13 1 2004 137 147
11. C.S. Via, A. Shustov, V. Rus, T. Lang, P. Nguyen, and F.D. Finkelman In vivo neutralization of TNF-α promotes humoral autoimmunity by preventing the induction of CTL J Immunol 167 12 2001 6821 6826
12. M. Aringer, and J.S. Smolen Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus Expert Opin Drug Saf 7 4 2008 411 419
13. M. Aringer, W.B. Graninger, G. Steiner, and J.S. Smolen Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: an open-label study Arthritis Rheum 50 10 2004 3161 3169
14. C.K. Edwards 3rd, T. Zhou, J. Zhang, T.J. Baker, and M. De Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α J Immunol 157 4 1996 1758 1772
15. C. Gordon, G.E. Ranges, J.S. Greenspan, and D. Wofsy Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice Clin Immunol Immunopathol 52 3 1989 421 434
16. ClinicalTrials.gov home page [ http://clinicaltrials.gov ].
17. A. Rahman, and D.A. Isenberg Systemic lupus erythematosus N Engl J Med 358 9 2008 929 939
18. C.D. Vedove, M. Del Giglio, D. Schena, and G. Girolomoni Drug-induced lupus erythematosus Arch Dermatol Res 301 1 2009 99 105
19. W. Rodriguez, C. Mold, M. Kataranovski, J. Hutt, L.L. Marnell, and T.W. Du Clos Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein Arthritis Rheum 52 2 2005 642 650